Incyte Corp (NASDAQ:INCY)

66.25
Delayed Data
As of Dec 14
 -1.04 / -1.55%
Today’s Change
58.33
Today|||52-Week Range
102.63
-30.05%
Year-to-Date
5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
Dec 14 / Zacks.com - Paid Partner Content
AstraZeneca's Imfinzi Fails in Head and Neck Cancer Study
Dec 07 / Zacks.com - Paid Partner Content
Roche to Create Companion Diagnostic Test for Merck's Keytruda
Dec 12 / Zacks.com - Paid Partner Content
Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger
Dec 06 / Zacks.com - Paid Partner Content
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Dec 10 / Zacks.com - Paid Partner Content
Incyte (INCY) Announces Positive Data on Jakafi for GVHD
Dec 04 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close67.29
Today’s open66.61
Day’s range65.66 - 67.64
Volume1,184,886
Average volume (3 months)1,491,713
Market cap$13.6B
Data as of 4:00pm ET, 12/14/2018

Growth & Valuation

Earnings growth (last year)-378.18%
Earnings growth (this year)+135.55%
Earnings growth (next 5 years)+47.45%
Revenue growth (last year)+38.93%
P/E ratioNM
Price/Sales12.61
Price/Book8.30

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...-0.78-0.83%
JAZZJazz Pharmaceuticals...-1.54-1.08%
PRGOPerrigo Company PLC-1.52-2.60%
SGENSeattle Genetics Inc-0.52-0.85%
Data as of 4:01pm ET, 12/14/2018

Financials

Next reporting dateFebruary 14, 2019
EPS forecast (this quarter)$0.19
Annual revenue (last year)$1.5B
Annual profit (last year)-$313.1M
Net profit margin-20.38%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts